comprar peptídeos ghk-cu 50mg Ampola Para Cuidado Corporal Rosto GHK-Cu 50mg – Buy Online

Order may take form of reference to District [***] Magistrate

Its a chain of amino acids that can tell specific cells to do certain things or act in a certain way, whether its regenerating tissues or affecting blood flow

SEQUENCE LISTING MEDIMMUNE LLC ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGS ORPEP-200-PSP US 62/579186 2017-10-31 15 PatentIn version 3.5 1 30 PRT Artificial Sequence GLP-1 7-36 1 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 20 25 30 2 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) AIB MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys((Peg)2-(Peg)2-gamma-Glu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 2 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 3 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) alpha-Me-Phe MOD_RES (20)..(20) Lys((Peg)2-(Peg)2-gamma-Glu-stearate) MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) alpha-Me-Phe MOD_RES (28)..(28) alpha-Me-Lys 3 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Phe Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Phe Val Val Lys Gly Gly 20 25 30 4 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) alpha-Me-Phe MOD_RES (20)..(20) Lys((Peg)2-(Peg)2-gamma-Glu-stearate) MOD_RES (25)..(25) alpha-Me-Phe MOD_RES (28)..(28) alpha-Me-Lys 4 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Phe Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Phe Val Val Lys Gly Gly 20 25 30 5 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (12)..(12) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 5 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Lys Tyr Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 6 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 6 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 7 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (12)..(12) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (26)..(26) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 7 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Lys Tyr Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Trp Lys Val Glu Gly Gly 20 25 30 8 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) MOD_RES MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (10)..(10) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (24)..(24) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 8 His Xaa Glu Gly Ser Phe Thr Ser Asp Lys Ser Ser Tyr Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Lys Trp Val Val Glu Gly Gly 20 25 30 9 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (14)..(14) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 9 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Tyr Lys Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 10 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys((PEG)2-(PEG)2-gammaGlu-Palmitoyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Palmitoyl) 10 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 11 31 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) aib MOD_RES (20)..(20) AEEAc-AEEAc-Gamma-Glu-17-carboxyheptadecanoyl 11 His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 20 25 30 12 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) Tyr(OMe) MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) 12 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Tyr Ile Ala Lys Val Val Glu Gly Gly 20 25 30 13 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) Nle MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) 13 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Xaa Ile Ala Lys Val Val Glu Gly Gly 20 25 30 14 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Myristoyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Myristoyl) 14 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 15 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Stearoyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Stearoyl) 15 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 SEQUENCE LISTING MEDIMMUNE LLC ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGS ORPEP-200-PSP US 62/579186 2017-10-31 15 PatentIn version 3.5 1 30 PRT Artificial Sequence GLP-1 7-36 1 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 20 25 30 2 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) AIB MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys((Peg)2-(Peg)2-gamma-Glu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 2 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 3 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) alpha-Me-Phe MOD_RES (20)..(20) Lys((Peg)2-(Peg)2-gamma-Glu-stearate) MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) alpha-Me-Phe MOD_RES (28)..(28) alpha-Me-Lys 3 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Phe Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Phe Val Val Lys Gly Gly 20 25 30 4 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) alpha-Me-Phe MOD_RES (20)..(20) Lys((Peg)2-(Peg)2-gamma-Glu-stearate) MOD_RES (25)..(25) alpha-Me-Phe MOD_RES (28)..(28) alpha-Me-Lys 4 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Phe Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Phe Val Val Lys Gly Gly 20 25 30 5 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (12)..(12) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 5 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Lys Tyr Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 6 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 6 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 7 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (12)..(12) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (26)..(26) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 7 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Lys Tyr Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Trp Lys Val Glu Gly Gly 20 25 30 8 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) MOD_RES MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (10)..(10) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (24)..(24) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 8 His Xaa Glu Gly Ser Phe Thr Ser Asp Lys Ser Ser Tyr Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Lys Trp Val Val Glu Gly Gly 20 25 30 9 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (14)..(14) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Lauroyl) 9 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Tyr Lys Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 10 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys((PEG)2-(PEG)2-gammaGlu-Palmitoyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys((PEG)2-(PEG)2-gammaGlu-Palmitoyl) 10 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 11 31 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) aib MOD_RES (20)..(20) AEEAc-AEEAc-Gamma-Glu-17-carboxyheptadecanoyl 11 His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 20 25 30 12 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) Tyr(OMe) MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) 12 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Tyr Ile Ala Lys Val Val Glu Gly Gly 20 25 30 13 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) Nle MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Lauroyl) 13 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Xaa Ile Ala Lys Val Val Glu Gly Gly 20 25 30 14 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic Polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Myristoyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Myristoyl) 14 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 15 30 PRT Artificial Sequence Description of Artificial Sequence: Synthetic polypeptide MOD_RES (2)..(2) Aib MOD_RES (6)..(6) alpha-Me-Phe MOD_RES (11)..(11) alpha-Me-Ser MOD_RES (13)..(13) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Stearoyl) MOD_RES (20)..(20) alpha-Me-Lys MOD_RES (22)..(22) alpha-Me-Phe MOD_RES (25)..(25) Lys(Epsilon-(PEG)2-(PEG)2-gammaGlu-Stearoyl) 15 His Xaa Glu Gly Ser Phe Thr Ser Asp Val Ser Ser Lys Leu Glu Gly 1 5 10 15 Glu Ala Ala Lys Glu Phe Ile Ala Lys Val Val Glu Gly Gly 20 25 30 Claims (41) Applications Claiming Priority (3) Publications (1) Family ID=66331379 Family Applications (1) Country Status (23) Cited By (1) Families Citing this family (6) Family Cites Families (9) 2018 2018-10-30 CN CN201880083797.2A patent/CN111655338A/en active Pending 2018-10-30 KR KR1020207014548A patent/KR20200081411A/en not_active Ceased 2018-10-30 SG SG11202003627PA patent/SG11202003627PA/en unknown 2018-10-30 US US16/760,250 patent/US11173124B2/en not_active Expired - Fee Related 2018-10-30 WO PCT/IB2018/058514 patent/WO2019087083A2/en not_active Ceased 2018-10-30 PE PE2020000457A patent/PE20210116A1/en unknown 2018-10-30 EA EA202091095A patent/EA202091095A1/en unknown 2018-10-30 CA CA3079376A patent/CA3079376A1/en not_active Abandoned 2018-10-30 MX MX2020004497A patent/MX2020004497A/en unknown 2018-10-30 CR CR20200185A patent/CR20200185A/en unknown 2018-10-30 AU AU2018360382A patent/AU2018360382A1/en not_active Abandoned 2018-10-30 JP JP2020524064A patent/JP2021501172A/en active Pending 2018-10-30 MA MA050047A patent/MA50047A/en unknown 2018-10-30 BR BR112020008220-1A patent/BR112020008220A2/en not_active Application Discontinuation 2018-10-30 EP EP18874364.5A patent/EP3703817A4/en not_active Withdrawn 2018-10-31 AR ARP180103167A patent/AR116451A1/en unknown 2018-10-31 TW TW107138546A patent/TW201932139A/en unknown 2020 2020-04-21 IL IL274096A patent/IL274096A/en unknown 2020-04-29 PH PH12020551018A patent/PH12020551018A1/en unknown 2020-04-29 CL CL2020001131A patent/CL2020001131A1/en unknown 2020-04-30 CO CONC2020/0005485A patent/CO2020005485A2/en unknown 2020-05-06 DO DO2020000082A patent/DOP2020000082A/en unknown 2020-05-27 ZA ZA2020/03149A patent/ZA202003149B/en unknown

During follow-up visits, the practitioner will assess your progress and make any necessary adjustments to your treatment plan